Dr. Martens plc (LON:DOCS - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday after Peel Hunt upgraded the stock to a buy rating. The company traded as high as GBX 86 ($1.16) and last traded at GBX 85.54 ($1.16), with a volume of 1096627 shares traded. The stock had previously closed at GBX 81.05 ($1.10).
Other analysts have also issued reports about the company. Royal Bank Of Canada lowered their price objective on Dr. Martens from GBX 7,000 to GBX 6,000 and set a "sector perform" rating for the company in a report on Monday, May 19th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Dr. Martens in a report on Friday, July 11th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of GBX 6,000.
Check Out Our Latest Stock Report on DOCS
Dr. Martens Price Performance
The company has a market capitalization of £884.85 million, a P/E ratio of 12.92, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The company has a fifty day moving average price of GBX 78.28 and a 200 day moving average price of GBX 65.79. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13.
Dr. Martens (LON:DOCS - Get Free Report) last posted its earnings results on Thursday, June 5th. The company reported GBX 2.40 EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, sell-side analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.
About Dr. Martens
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.
Recommended Stories
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
